Terns Pharmaceuticals
TERNNASDAQSmall molecule drug development
Drafted with AI assistance from public sources and not individually reviewed by an editor; last updated 2026-09-09. Published by Blane Jackson, DDS, MBA. Educational analysis only. Read the editorial policy and disclosures.
text updated 2026-09-09 · archived: kept for reference, not maintained · where each field comes from
Key figures from SEC filings
Upcoming catalysts
No upcoming catalyst for Terns Pharmaceuticals has been confirmed against a primary source. Rather than estimate one, this section is left empty — check the company's investor relations page and ClinicalTrials.gov directly.
Pipeline
| Drug | Indication | Phase | Expected data | |
|---|---|---|---|---|
| TERN-701 | Chronic Myeloid Leukemia (CML) | Phase 1 | Not disclosed | ▼ |
| TERN-501 | Thyroid Eye Disease (TED) | Phase 2 | H2 2026 | ▼ |
What does Terns Pharmaceuticals do?
Terns Pharmaceuticals is a small biotech company working on treatments for cancer, specifically a type of blood cancer called chronic myeloid leukemia (CML). Their main drug, TERN-701, is designed to block a protein that causes cancer cells to grow. Unlike older drugs, it attaches to a different part of the protein, which might help patients who have become resistant to current treatments. They also have a drug for an eye condition related to thyroid disease. For investors, Terns is a high-risk, high-reward bet: if their lead drug works well in clinical trials, it could become a major player in a multi-billion dollar market. But they face tough competition from an already-approved drug called asciminib, and they have no products on the market yet. The company has enough money to operate for about two years, but they'll need positive trial results to keep going. Keep an eye on their upcoming data releases, which could cause big stock price swings.
What to watch
Monitor for updated TERN-701 phase 1 data at major conferences like ASH or ASCO.
Track enrollment and dosing progress in the phase 1 trial via clinicaltrials.gov.
Watch for any announcements of partnerships or licensing deals for TERN-701.
Follow quarterly earnings calls for updates on cash runway and pipeline strategy.
Investment thesis
High RiskBull case
Terns Pharmaceuticals is developing TERN-701, a potentially best-in-class allosteric inhibitor for CML, a well-established market with clear regulatory pathways. Early data suggest it may be more potent and safer than existing therapies, including asciminib. With a strong cash position and a second asset in TED, Terns offers multiple shots on goal. If TERN-701 demonstrates superiority in ongoing trials, it could capture significant market share and lead to a lucrative partnership or acquisition. The company's experienced management team and focus on precision medicine align with current oncology trends.
Bear case
Terns faces intense competition from Novartis's asciminib, which is already approved and has a head start. TERN-701 is still in early stages, and clinical data may not replicate preclinical promise. The CML market is relatively mature, and payers may be reluctant to switch patients without clear advantages. Additionally, Terns has no approved products and relies heavily on TERN-701's success; any clinical hold or safety issue could devastate the stock. The TED program is also competitive, with Amgen's Tepezza dominating. Terns may need to raise capital, diluting shareholders.
Risk factors
Clinical trial failure or delay for TERN-701
Competitive pressure from asciminib and other CML therapies
Dependence on single lead asset for near-term value
Potential safety issues in early trials
Need for additional financing if trials expand
Comparable companies
Sponsored
Get premium TERN analysis on Seeking AlphaAffiliate link — we may earn a commission at no cost to you